Literature DB >> 8373546

[Risk factors of necrotizing enterocolitis].

C A Tapia-Rombo1, M R Velasco-Lavín, A Nieto-Caldelas.   

Abstract

The purpose of the present study is to compare risk factors of necrotizing enterocolitis (NEC) between two group: group A, newborns with the disease and group B, newborns with other diseases different from NEC, in order to know if these risk factors are more frequent or not in the first group. We assessed the clinical records of all the patients hospitalized in the Neonatal Intensive Care Unit and Neonatology Service of the La Raza General Hospital between 1987 and 1991 with the diagnosis of NEC. They were compared with 65 clinical records chosen at random of patients hospitalized in the same Unit with other diagnosis at the same time, and who were discharged by improvement or deceased. In all of them were look for known risk factors for NEC generally accepted such as: prematurity, neonatal asphyxia, poliglobulia, cyanotic congenital heart disease, patent ductus arteriosus, respiratory distress syndrome, catheterization of umbilical vessels, early feeding of elevated formula increases, exchange exchange transfusion, hypoxic ischemic encephalopathy, infection, etc. Just 25 records of the possible 50 with the diagnosis of NEC full filled inclusion criteria. There were no statistically significant difference in weight, sex, mortality and known risk factors of NEC between both groups. Were concluded that NEC is a disease of unknown etiology that should be studied more thoroughly. The known risk factors must be avoided because the patient susceptibility probably play an important role.

Entities:  

Mesh:

Year:  1993        PMID: 8373546

Source DB:  PubMed          Journal:  Bol Med Hosp Infant Mex        ISSN: 0539-6115


  1 in total

1.  Temporal and seasonal variations in incidence of stage II and III NEC-a 28-year epidemiologic study from tertiary NICUs in Connecticut, USA.

Authors:  Darius Javidi; Zigeng Wang; Sanguthevar Rajasekaran; Naveed Hussain
Journal:  J Perinatol       Date:  2021-02-15       Impact factor: 2.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.